Explore the Latest Active Ingredient Tenders on Tender Impulse - Your Trusted Global Tender Website
Are you searching for the latest Active Ingredient Tenders from trusted sources across the globe? Tender Impulse is the go-to tender website for businesses seeking verified, timely updates on public tenders, government tenders and business tenders.
With real-time data and smart filters, you can find the most relevant Active Ingredient Tenders issued by ministries, public sector organisations and international procurement agencies - whether you're an SME or a multinational.
All-in-One Platform for Active Ingredient Tenders
- Requests for Proposals (RFPs) & Quotations (RFQs)
- General Procurement Notices (GPNs) & Expressions of Interest (EOIs)
- Prequalification documents, contract awards and amendments
Why Choose Tender Impulse?
- Custom email alerts tailored to your industry.
- Global coverage across 190+ countries and every major sector.
- Instant document access - specifications, BOQs and tender forms.
- Advanced filters by country, industry, deadline, value and procurement type.
Request a free live demo today and explore thousands of Active Ingredient Tenders and beyond.
11007427Conclusion of a non-exclusive discount agreement in accordance with section 130a paragraph 8 sgb v for the active ingredient metronidazole atc d06bx01 for the period march 1 2026Country: GermanyDeadline05 Jan 202911007436Conclusion of a non-exclusive discount agreement in accordance with section 130a paragraph 8 sgb v for the active ingredient potassium iodide atc h03ca01 for the period march 1 2Country: GermanyDeadline05 Jan 202911007457Conclusion of a non-exclusive discount agreement in accordance with section 130a paragraph 8 sgb v for the active ingredient budesonide atc a07ea06 for the period march 1 2026 -Country: GermanyDeadline05 Jan 20297537423Cinnarizin und dimenhydrinatCountry: GermanyDeadline06 Mar 20278708573Completion of a non -exclusive discount agreement according to section 130a 8 sgb v on the active ingredient amifampridine atc n07xx05 for the period 01 09 2025 - 31 08 2027 plCountry: GermanyDeadline05 Jul 20288708582Completion of a non-exclusive discount agreement according to section 130a 8 sgb v for the active ingredient naproxen esomeprazol atc m01ae52 f d z 01 09 2025 - 31 08 2027Country: GermanyDeadline05 Jul 202811007454Conclusion of a non-exclusive discount agreement in accordance with section 130a paragraph 8 sgb v for the active ingredient isosorbide mononitrate atc c01da14 for the period marcCountry: GermanyDeadline05 Jan 202910367860AlfacalcidolCountry: GermanyDeadline06 Dec 20279462970Medicines with the active ingredient infliximab atc l04ab02 - in the dosage form injection solutionCountry: GermanyDeadline31 Aug 202710243493Medicines with the active ingredient pazopanib atc l01ex03Country: GermanyDeadline31 Oct 202710243496Medicines with the active ingredient combination timolol and tafluprost atc s01ed70Country: GermanyDeadline31 Oct 202710244223Medicines with the active ingredient raltegravir atc j05aj01Country: GermanyDeadline31 Oct 202710244287Medicines with the active ingredient tafluprost atc s01ee05Country: GermanyDeadline31 Oct 20278416471Description : The health insurance companies (whether HEK and/or hkk are participating in the respective lot is determined by the name of the respective lot) aim to conclude discoCountry: GermanyDeadline31 Aug 20264161673Conclusion of non-exclusive discount agreements in accordance with Section 130a Paragraph 8 SGB V for those mentioned
Active ingredientCountry: GermanyDeadline31 Dec 20264161790Conclusion of non-exclusive discount agreements in accordance with Section 130a Paragraph 8 SGB V for those mentioned
Active ingredientCountry: GermanyDeadline31 Dec 202613381585Open house drug discount agreements for the active ingredient lisdexamfetamine without hard capsules in a pack size of 30 atc n06ba12Country: GermanyDeadline01 Jun 20286488782The Commercial Health Insurance Fund - KKH (hereinafter KKH) aims to conclude discount agreements in accordance with Section 130a Paragraph 8 SGB V for the active ingredient(s) witCountry: GermanyDeadline31 Dec 20266490408Conclusion of non-exclusive drug discount agreement according to Section 130a Paragraph 8 SGB V by means of an open-house model for the active ingredient sevelamer hydrochloride (ACountry: GermanyDeadline31 Jan 20276542053The Commercial Health Insurance Fund - KKH (hereinafter KKH) aims to conclude discount agreements in accordance with Section 130a Paragraph 8 SGB V for the active ingredient(s) witCountry: GermanyDeadline31 Dec 20266572616Conclusion of a non-exclusive drug discount agreement pursuant to Section 130a Paragraph 8 of the Social Code Book V by means of an open-house model for the active ingredient BecloCountry: GermanyDeadline31 Jan 20276605104Medicinal products containing the active ingredient secukinumab (ATC: L04AC10)Country: GermanyDeadline30 Nov 20266605127Medicinal products containing the active ingredient mesalazine (ATC: A07EC02)Country: GermanyDeadline30 Nov 20266605576Conclusion of a non-exclusive discount agreement pursuant to Section 130a Paragraph 8 SGB V for medicinal products containing the active ingredient aripiprazole as a depot injectioCountry: GermanyDeadline27 Nov 20266605587Medicinal products containing the active ingredient leuprorelin (ATC: L02AE02)Country: GermanyDeadline30 Nov 2026
